Adaptimmune Annual report [Section 13 and 15(d), not S-K Item 405]

Share-based compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 12,051	$ 11,773	$ 18,240
Research and development
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	3,875	3,061	6,264
Selling, general and administrative
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 8,176	$ 8,712	$ 11,976